Smarcc1 expression: A significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure
Smarcc1 expression: A significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure
复制标题
DOI：
10.3109/00365599.2010.530295
复制
发表时间：
2011-03-01
影响因子：
--
通讯作者：
Borre, Michael
中科院分区：
文献类型：
--
作者：
Hansen, Rehne Lessman;Heeboll, Sara;Borre, Michael
客观的。前列腺癌（PC）的临床结果变化极大，因此在疾病早期很难预测。由于治疗性疗法与严重不良事件的风险密切相关，因此识别 PC 中新的预后标志物对于个体化临床治疗至关重要。 Smarcc1 蛋白是核内 SWI/SNF 复合物的一部分，在 PC 中表达上调，并被认为与肿瘤去分化、进展和生化复发有关。这使得 Smarcc1 成为 PC 生存的可能候选标记。材料和方法。使用免疫组织化学方法测量组织微阵列上 Smarcc1in 的蛋白表达水平，该组织微阵列包含来自 100 名患有临床局限性 PC 的患者的样本，这些患者在接受治疗后无意治愈并随后死亡。结果。诊断时的中位年龄为75.5岁（55--95岁），中位生存时间为5年（0.01--15年）。总共有 41 名患者 (41%) 死于 PC。从统计上看，Smarcc1 免疫染色（阴性/阳性）与 Gleason 评分 (p == 0.7/0.8) 或临床 T 分期 (p == 0.9) 之间没有显着相关性。与阴性染色相反，临床局限性 PC 患者中 Smarcc1 的阳性染色与延长的无病生存期相关 (p == 0.025)。结论。在接受无治愈目的的临床局限性 PC 患者中，Smarcc1 表达是疾病特异性生存的统计学显着且独立的预测因子。
Objective. The clinical outcome of prostate cancer (PC) is extremely variable and therefore difficult to predict at the early stage of the disease. Since curative-intended therapies are bound up with the risk of severe adverse events, identification of new prognostic markers in PC is essential in individualized clinical treatment. The Smarcc1 protein, a part of the intranuclear SWI/SNF complex, is up-regulated in PC, and has been suggested to be implicated in tumour dedifferentiation, progression and biochemical recurrence. This makes Smarcc1 a possible candidate marker for PC survival. Material and methods. Immunohistochemistry was used to measure protein expression levels of Smarcc1in on a tissue microarray containing specimens from 100 patients suffering from clinically localized PC treated with no intention to cure and followed to death. Results. The median age at diagnosis was 75.5 years (55--95 years) and the median survival time was 5 years (0.01--15 years). In total, 41 patients (41%) died of PC. Statistically, there was no significant association between Smarcc1 immunostaining (negative/positive) and Gleason score (p == 0.7/0.8) or the clinical T stage (p == 0.9). Positive staining for Smarcc1 in patients with clinically localized PC correlated with a prolonged disease-free survival as opposed to negative staining (p == 0.025). Conclusion. In patients with clinically localized PC treated without intention of cure, Smarcc1 expression was a statistically significant and independent predictor of disease-specific survival.